Quarterly report pursuant to Section 13 or 15(d)

Nature of Operations and Summary of Significant Accounting and Reporting Policies (Details Narrative)

v3.7.0.1
Nature of Operations and Summary of Significant Accounting and Reporting Policies (Details Narrative) - USD ($)
 3 Months Ended 9 Months Ended
Mar. 31, 2017
Mar. 31, 2016
Mar. 31, 2017
Mar. 31, 2016
Jun. 30, 2016
Accumulated Other Comprehensive Income (Loss) [Line Items]          
Common stock, shares authorized 100,000,000   100,000,000   100,000,000
Common stock, par value $ 0.001   $ 0.001   $ 0.001
Cash and cash equivalents    
Value added tax receivable 10,125   10,125   $ 29,355
Research and development expense $ 386,490 $ 510,301 $ 714,889 $ 806,578  
Employee Stock Option [Member]          
Accumulated Other Comprehensive Income (Loss) [Line Items]          
Antidilutive securities excluded from computation of earnings per share, amount     572,000    
Warrant [Member]          
Accumulated Other Comprehensive Income (Loss) [Line Items]          
Antidilutive securities excluded from computation of earnings per share, amount     149,517    
Common Stock [Member]          
Accumulated Other Comprehensive Income (Loss) [Line Items]          
Antidilutive securities excluded from computation of earnings per share, amount     1,600,288    
Australian Taxation Office [Member]          
Accumulated Other Comprehensive Income (Loss) [Line Items]          
Research and development expense     $ 306,159 $ 71,970  
April 20, 2017 [Member]          
Accumulated Other Comprehensive Income (Loss) [Line Items]          
Reverse stock split     one-for-two hundred and fifty (1:250)    
Common stock, shares authorized 100,000,000   100,000,000    
Common stock, par value $ 0.001   $ 0.001    
Preferred stock, shares authorized 1,500,005   1,500,005